
- | SCYNEXIS
The 10 most innovative medicine and therapeutics companies of 2022
To combat the problem of antifungal resistance, Scynexis developed an entirely new class of fungicide: triterpenoid antifungal, which doctors can prescribe when first-line azole treatments don’t work.

- | Anixa Biosciences
Highlighting Innovation in Breast and Ovarian Cancer on International Women’s Day
Anixa recently launched a Phase I trial of its breast cancer vaccine in patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence.

- | AltruBio Inc.
Three Influential Women of Biopharma Breaking Down the Executive Barrier
Her company AltruBio focuses on novel therapeutics for immunological diseases, concentrating on unmet medical needs. The company’s lead candidate, therapeutic antibody neihulizumab, has demonstrated clinical proof of efficacy in treating multiple autoimmune and immune-mediated diseases.

- | TFF Pharmaceuticals
Catalent expands inhalation efforts in collaboration with Texas-based pharma
TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that.

- | Anima Biotech
Software driven biology for small molecule mRNA drugs, Yochi Slonim, Co-founder & CEO, Anima
A serial entrepreneur in software and biotech, Yochi Slonim has built multiple companies as a founder and CEO through all phases of growth all the way to IPOs and large M&A exits. As a Co-founder and CEO of Anima Biotech, he is driving the company’s vision and strategy, fundraising, and partnering.

- | MindMed
Comparing the acute effects of LSD and psilocybin
Executive president of MindMed, Miri Halperin Wernli, PhD, added: “LSD and psilocybin have recently become promising candidates for the treatment of various psychiatric and neurologic disorders, and thus a deeper understanding of their differential subjective effects in humans is needed.

- | Cerevance
Uncovering New Drug Targets for Neurological Diseases
Cerevance has developed its proprietary, Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to analyze postmortem human brain tissues to produce rich cell type–specific data sets.

- | Portage Biotech
What Makes for Successful Collaborations Between Big and Small Pharma?
Portage Biotech: Clinical-stage oncology company dedicated to sourcing and acquiring the most promising early-stage assets available to build a pipeline of first-in-class/best-in-class therapeutic candidates. Currently, has well-established partnerships with both Bristol Myers Squibb and Merck.